Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK

British Journal of Psychiatry

Volumn 182, Issue JUNE, 2003, Pages 505-508

  Duggan, Andy ^a   Warner, Juliet ^a   Knapp, Martin ^b   Kerwin, Robert ^b  

^a Decision Resources Group   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ARTICLE; CLINICAL FEATURE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LENGTH OF STAY; PATIENT COMPLIANCE; PRESCRIPTION; SCHIZOPHRENIA; SUICIDE; SUICIDE ATTEMPT; TREATMENT OUTCOME; UNITED KINGDOM;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HEALTH RESOURCES; HOSPITALIZATION; HUMAN; LIFE TABLES; MODELS, STATISTICAL; PREVALENCE; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUICIDE; SUPPORT, NON-U.S. GOV'T;

EID: 0037680436     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.182.6.505     Document Type: Article

References (21)

1. Adams, C. (1999) Drug Treatments for Schizophrenia. Effective Health Care. York: NHS Centre for Reviews and Dissemination, University of York.
2. Addington, D. E. & Addington, J. M. (1992) Attempted suicide and depression in schizophrenia. Acta Psychiatrica Scandinavica, 85, 288-291.
3. Aitchison, K. J. & Kerwin, R.W. (1997) Cost-effectiveness of clozapine. A UK clinic-based study. British Journal of Psychiatry, 171, 125-130.
4. Appleby, L. (1999) Safer Services: National Confidential Inquiry into Suicide and Homicide by People with Mental Illness. London: Department of Health.
5. Davies, L. M. & Drummond, M. F. (1993) Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. British Journal of Psychiatry, 162, 38-42.
6. Department of Health (1996) Hospital Episode Statistics. London: DoH.
7. _ (1999) Saving Lives: Our Healthier Nation (Cm 4386). London: Stationery Office.
8. Guest, J. F. & Cookson, R. F. (1999) Cost of schizophrenia to UK society An incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics, 15, 597-610.
9. Knapp, M., Chisholm, D., Leese, M., et al (2002) Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Acta Psychiatrica Scandinavica, 105, 42-54.
10. Meltzer, H.Y. (1991) Treatment-resistant schizophrenia - the role of clozapine. Current Medical Research and Opinion, 14, 1-20.
11. _ & Okayli, G. (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. American Journal of Psychiatry, 152, 183-190.
12. _, Burnett, S., Bastani, B., et al (1990) Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry, 41, 892-897.
13. _, Cola, P., Way, L., et al (1993) Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. American Journal of Psychiatry, 150, 1630-1638.
14. Modestin, J., Zarro, I. & Waldvogel, D. (1992) A study of suicide in schizophrenic in-patients. British Journal of Psychiatry, 160, 398-401.
15. Munro, J., O'Sullivan, D., Andrews, C., et al (1999) Active monitoring of 12 760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. British Journal of Psychiatry, 175, 576-580.
16. National Institute for Clinical Excellence (2002) Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance 43. London: NICE.
17. Netten, A. & Dennett, J. H. (1996) Unit Costs of Health and Social Core. Canterbury: Personal Social Services Research Unit, University of Kent.
18. Revicki, D. A. (1999) Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophrenia Research, 35 (suppl.), S101-109.
19. Rosenheck, R., Cramer, J., Xu, W., et al (1997) A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Group on Clozapine in Refractory Schizophrenia. New England Journal of Medicine, 337, 809-815.
20. Turner, T. (1997) ABC of mental health: schizophrenia. BMJ, 315, 108-111.
21. Wahlbeck, K., Cheine, M., Essali, A., et al (1999) Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. American Journal of Psychiatry, 156, 990-999.